As part of our strategic evolution, EnnoDC has become the new trading name of LinKinVax. We’re expanding our dendritic cell targeting technology and development programs beyond infectious diseases to innovative cancer treatments.

EnnoDC has a broad pipeline of first-in-class clinical and preclinical stage development programs in HPV-induced cancers, prostate cancer and in infectious diseases.

To learn more about our exciting developments.